Avid Bioservices Inc (CDMO)

[biopharm]

ECG, the IP assets and contracts are completed and IF the IP assets had no value...then Avid Bioservices CDMO would not have 15% about to net sales on any approvals and wouldn't have been guaranteed ALL manufacturing

I guess some like to still ...create fog ...as the IP is not only Bavituximab and not only Targeting of PS

The IP assets and patent expiration is simply a smoke and mirrors ...as I have already explained how extensions come into play

____

Gla domains as targeting agents

United States
The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.
The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.

Terry Hermiston
CEO at GLAdiator Bioscience
GLAdiator BiosciencesUniversity of Iowa
Richmond, California500+ connections

Experience
GLAdiator Biosciences
CEO
GLAdiator Biosciences
Aug 2018 – Present
1 year 4 months
....
Based on a 2 year collaboration between Bayer HealthCare and Stanford University, the company is centered on a unique biologics platform that targets and internalizes into cells expressing phosphatidylserine (PS) on their cell surface.
...
...

_____


Patents and extensions...

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152151696

_______

If Dana Farber and Gordon Freeman thought like some here....his work would have never been recognized and the IP assets all held by Peregrine ....where Avid CDMO receives royalties 15% and manufacturing etc...is pending big right now

_______

Why do you think Omeros comes forward now to admit PS Targeting is REQUIRED?

https://www.marketwatch.com/press-release/omeros-discovers-new-cancer-immunity-pathways-controlled-by-gpr174-2019-09-10?mod=mw_quote_news